The study under scrutiny, led by Stefania Brogini and colleagues and published earlier in the same journal, evaluated a sol–gel zirconia–silver coating applied to titanium implants. The coating is designed to address a persistent clinical problem: implant-associated infections. Silver ions are potent antibacterial agents, and embedding silver within a ceramic zirconia matrix offers a way to deliver that antimicrobial activity at the implant surface without releasing enough metal to harm surrounding tissue. The original research reported an integrated assessment covering biocompatibility, short-term antibacterial efficacy, and osseointegration, the process by which living bone grows into direct contact with an implant surface. The authors concluded that osseointegration was preserved despite the addition of silver, a finding with obvious appeal for anyone hoping to design implants that resist infection without compromising fixation.

Yang and Zhang’s concern begins with a discrepancy in the numbers. According to the methods section of the original paper, the animal experiment involved 12 control and 12 coated implant sites distributed across 17 rats. Yet Table 2 of that paper reports 14 observations for the control group and 19 for the coated group when measuring bone-to-implant contact, the standard histological metric of osseointegration. The letter writers ask a deceptively simple question: what do those numbers represent? Are they individual implants, histological sections, microscopic images, or regions of interest within images? Each answer carries different statistical consequences, and the distinction matters enormously for how much confidence the results deserve.

The issue at stake is what statisticians call the experimental unit, the smallest entity to which a treatment is independently applied and which can serve as the basis for a valid comparison. In an implant study, the experimental unit is typically the individual animal, or at minimum the individual implant, because two implants placed in the same rat share the same circulation, immune system, healing capacity, and local bone environment. Measurements taken from multiple sections or images of the same implant are not independent observations; they are repeated measures that inflate the apparent sample size if treated as separate data points. This problem, sometimes called pseudoreplication, has been documented across cell culture and animal research, and it was the subject of a widely cited 2018 analysis in PLOS Biology by Stacy Lazic and colleagues asking what exactly the N means in such experiments.

If the 14 and 19 values in the zirconia–silver study represent histological sections or images rather than implants, the effective sample size could be far smaller than the table suggests, and the reported confidence intervals and P values would be optimistically narrow. Yang and Zhang also note that the original paper does not explain how within-animal dependence was handled, meaning whether observations from implants placed in the same rat were statistically linked. Modern guidelines for reporting animal research, including the ARRIVE 2.0 framework published in PLOS Biology in 2020, explicitly require researchers to specify the experimental unit and account for clustering, precisely because these choices determine whether a study’s statistics are interpretable at all.

The second pillar of the letter concerns a subtler but equally important point about how null results are described. The original study reported no significant difference in bone-to-implant contact between coated and control implants, with a P value of 0.84. On its face, that looks like strong evidence that the coating did nothing harmful. But Yang and Zhang point out that a non-significant difference test with a broad confidence interval does not, by itself, establish that the coating preserves osseointegration. A high P value simply means the data did not detect a difference; it does not mean the data excluded the possibility of a meaningful one. This is the classic statistical trap memorably summarized by Douglas Altman and Martin Bland in a 1995 British Medical Journal editorial: absence of evidence is not evidence of absence.

The proper tool for the claim the original authors wanted to make is a noninferiority test, in which researchers prespecify an acceptable margin, the largest reduction in bone-to-implant contact that would still be considered clinically tolerable, and then demonstrate statistically that the true difference is very likely smaller than that margin. Equivalence and noninferiority testing, as explained in a widely used primer by Eugene Walker and Amy Nowacki, requires the margin to be defined before the data are collected and the analysis to be framed around it. Without such a prespecified margin, concluding that a coating preserves osseointegration from a simple failure-to-reject analysis conflates two very different states of knowledge: failing to find a harm, and demonstrating that harm is absent or acceptably small.

What makes this exchange notable is its constructive tone and its practical implications. Yang and Zhang emphasize that the clarifications they seek require no new experiments, no additional animals, and no re-analysis beyond a transparent accounting of what was measured and how. If the 14 and 19 observations are indeed sections or images, the authors could reanalyze the data with the implant or animal as the unit, report the clustered structure, and, if appropriate, conduct a formal noninferiority analysis with a justified margin. Such a response would either shore up the original conclusion or appropriately temper it, and either outcome would strengthen the translational value of a coating technology that many in the implant field are watching closely.

The broader lesson extends well beyond zirconia–silver coatings. Implant surface research is a crowded and competitive field, with antimicrobial coatings, nanostructured textures, and bioactive chemistry all vying for clinical translation. Every one of these technologies must eventually clear the same bar: proof that the functional addition, whether silver ions or surface topography, does not compromise the biological integration that keeps an implant anchored for decades. Histomorphometric studies in rodents are the standard early evidence, and their statistical integrity depends on getting the experimental unit right. When sample sizes are small, as they inevitably are in animal work, the difference between counting implants and counting images can flip a conclusion from convincing to questionable.

Yang and Zhang close their letter by framing the issue as one that affects readers planning future implant surface evaluations, and their argument is likely to resonate with reviewers, editors, and funders who have pushed for stricter statistical hygiene in preclinical research. The letter, which received no external funding and declares no competing interests, was reviewed under Associate Editor Joel Stitzel and accepted within eleven days of submission, a pace suggesting the journal viewed the methodological point as substantive. Whether the original authors respond with a reanalysis or a clarification, the exchange serves as a compact teaching case for the field: report what your N truly is, account for the animals behind your numbers, and never mistake a wide confidence interval for a clean bill of health. In implant research, where the endpoint is measured in years of patient function, that distinction is not pedantry. It is the difference between a coating that is genuinely ready for the clinic and one that simply has not yet been proven otherwise.

Subject of Research: Statistical methodology and experimental unit analysis in a zirconia–silver titanium implant coating study

Article Title: Clarifying the Experimental Unit and the Evidence for Preserved Osseointegration in a Zirconia–Silver Coating Study

Article References: Clarifying the Experimental Unit and the Evidence for Preserved Osseointegration in a Zirconia–Silver Coating Study. (n.d.). https://doi.org/10.1007/s10439-026-04410-4

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04410-4

Keywords: titanium implants, zirconia-silver coating, osseointegration, experimental unit, pseudoreplication, noninferiority testing, bone-to-implant contact, antibacterial coatings, ARRIVE guidelines, animal research statistics, implant-associated infection, Annals of Biomedical Engineering

A new multicenter study led by Seifollah Gholampour of the University of Chicago Medicine and David F. Bauer of Texas Children’s Hospital, published in the Annals of Biomedical Engineering, tackles precisely this problem. Drawing on 150 pediatric patients treated at four major U.S. hospitals—Boston Children’s Hospital, Cedars-Sinai Medical Center, Oregon Health & Science University’s Doernbecher Children’s Hospital, and Texas Children’s Hospital—the research team assembled a dataset of 34 clinical, demographic, and imaging variables for each child. They then ran a head-to-head competition: traditional penalized statistical inference, in the form of ridge regression and generalized additive models, against nine cost-sensitive machine learning classifiers, with the best performers combined into a stacked ensemble. Crucially, they wrapped the winning model in an explainable artificial intelligence framework so that its reasoning could be inspected rather than taken on faith.

The results were striking. The stacked ensemble achieved an accuracy and macro-F1 score of 0.77 on held-out test data, with stable generalization across validation folds. More telling was the comparison of discrimination, the model’s ability to separate children who would need surgery from those who would not. For cranial surgery, the ensemble’s area under the receiver operating characteristic curve reached 0.78, compared with just 0.68 for the generalized additive model baseline. For spinal surgery the gap was similar: 0.76 versus 0.66. Calibration, meaning the alignment between predicted probabilities and observed outcomes, was acceptable, and decision curve analysis showed positive net benefit across clinically relevant thresholds for both outcomes. In practical terms, the machine learning approach made meaningfully fewer errors in the scenarios that matter most for surgical planning.

Why should a modestly larger cohort than a traditional statistician might demand still favor machine learning? The answer lies in the structure of the data itself. Rare diseases produce small, class-imbalanced datasets in which only a fraction of patients undergo surgery, and the relationships between predictors and outcomes are rarely linear or independent. A foramen magnum that is critically narrow may matter far more in an infant with hydrocephalus than in an older child without it. Achondroplasia’s phenotype, driven by a well-characterized mutation in the FGFR3 gene, produces a constellation of interacting features—frontal bossing, sleep-disordered breathing, Chiari malformation, back pain—whose joint effects defy simple additive models. Ensemble classifiers, which combine many weak learners, are built to capture such nonlinear dependencies and interactions, provided their outputs can be made transparent enough for clinicians to trust.

Transparency came through SHAP, or SHapley Additive exPlanations, a technique rooted in cooperative game theory that assigns each predictor a contribution value for every individual prediction. When the researchers applied SHAP to the best-performing model, the resulting explanations mapped closely onto clinical intuition while also revealing subtleties that conventional inference had missed. For cranial surgery, the dominant drivers were foramen magnum stenosis, hydrocephalus, family history, frontal bossing, sleep disturbance, and age. For spinal surgery, the leading contributors were spinal stenosis, Chiari malformation, family history, back pain, foramen magnum stenosis, and age. These class-specific profiles matter because they tell surgeons not merely what the model got right, but which features of a given child’s presentation pushed the prediction toward or away from intervention.

Perhaps the most scientifically interesting finding concerns age. In the classical inferential baselines, age did not reach statistical significance as a standalone predictor. Yet SHAP dependence patterns showed that the model attributed importance to age in a context-dependent way: the effect of age on surgical risk depended on whether a child had foramen magnum or spinal stenosis, rather than acting as an independent risk factor. This is exactly the kind of interaction a linear or additive model is designed to smooth away, and its recovery illustrates why the authors argue that explainable machine learning captures clinically contextualized predictive structure that penalized inference can obscure.

The comparison also exposed a provocative asymmetry. Several predictors highlighted prominently by SHAP—sleep disturbance, back pain, and age—were statistically nonsignificant in the inferential baselines. To a traditional biostatistician, that discrepancy might look like a red flag; to the study’s authors, it is evidence that the two frameworks answer different questions. Penalized inference asks which variables show a population-average marginal association, subject to strict regularization and significance testing. The ensemble-plus-SHAP pipeline asks which variables shift individualized risk estimates, including through interactions. Both perspectives carry information, and the study’s dual-stream benchmark was deliberately designed to make that contrast explicit and reproducible rather than to declare a single winner.

The stakes of getting these predictions right are high. Achondroplasia affects roughly one in every 20,000 to 30,000 births worldwide, and its neurosurgical complications have historically driven much of its excess mortality. Compressed brainstem and upper cervical cord in infants can cause central apnea and sudden death, while progressive spinal stenosis in older children can lead to irreversible neurological deficits. Kaplan–Meier analyses in the new study showed that children the model classified as high-risk underwent surgery significantly earlier than those in lower-risk strata, suggesting that the model’s risk scores align with real clinical timelines. A validated preoperative prediction tool could therefore help standardize referral patterns across the handful of specialized skeletal dysplasia centers that handle these cases, and could help families and clinicians structure surveillance schedules around quantified risk rather than intuition alone.

The study is also notable for how honestly it confronts the limitations of machine learning in rare-disease settings. The literature on medical AI is littered with models that report glittering cross-validation numbers but fail on external data, a problem amplified when event counts per variable fall below classical thresholds. The authors addressed class imbalance with cost-sensitive learning rather than naive synthetic oversampling, an approach consistent with their own prior work questioning the clinical validity of techniques like SMOTE on medical data. They evaluated not only discrimination but also calibration and clinical decision curves, and they compared nine candidate classifiers against a proper inferential baseline rather than a straw man. The centralized ethics approval across all four participating institutions, with de-identified retrospective data, allowed a cohort size that no single center could have assembled.

What emerges is less a finished clinical tool than a template for how predictive modeling should be done when data are scarce, imbalanced, and phenotypically messy. By benchmarking statistical inference against explainable AI under explicit rare-disease constraints, and by insisting that every prediction come with a decomposition of its drivers, the team has produced a reproducible framework that other rare-disease researchers can adapt. For children with achondroplasia, the near-term hope is that risk stratification for foramen magnum decompression and spinal surgery becomes earlier, more consistent, and better communicated. For the broader field of clinical machine learning, the message is sharper still: in rare disease, the models that earn clinical trust will not be the most accurate black boxes, but the ones whose reasoning surgeons can read, question, and act upon.

Subject of Research: Explainable AI versus statistical inference for predicting craniospinal surgery in pediatric achondroplasia

Article Title: Predicting Craniospinal Surgery in Pediatric Achondroplasia: Benchmarking Statistical Inference and Explainable AI Under Rare-Disease Constraints

Article References: Gholampour, S., Huang, J., Keusch, D., Lopes, C., Masarwy, A., Obayashi, J., Ruppert-Gomez, M., Sayama, C. M., Baird, L. C., Danielpour, M., & Bauer, D. F. (2026). Predicting Craniospinal Surgery in Pediatric Achondroplasia: Benchmarking Statistical Inference and Explainable AI Under Rare-Disease Constraints. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04352-x

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04352-x

Keywords: achondroplasia, pediatric neurosurgery, explainable AI, SHAP, machine learning, foramen magnum stenosis, spinal stenosis, surgical risk prediction, clinical decision support, rare disease, generalized additive models, Annals of Biomedical Engineering